This site is intended for healthcare professionals
Drug information

Co-trimoxazole

POM
Read time: 20 mins
Last updated: 20 Aug 2020
Published: 20 Aug 2020

4.1 Therapeutic indications

Co-trimoxazole should only be used where, in the judgement of the physician, the benefits of treatment outweigh any possible risks; consideration should be given to the use of a single effective antibacterial agent.

Co-trimoxazole is an antibacterial agent. Co-trimoxazole is effective in vitro against a wide range of gram-positive and gram-negative organisms. It is not active against Mycobacterium tuberculosis, mycoplasma or Treponema pallidum, Pseudomonas aeruginosa is usually insensitive.

Co-trimoxazole is indicated for the treatment of adults, adolescents and children from 6 years of age.

Co-trimoxazole is indicated for the treatment of the following infections when owing to sensitive organisms (see section 5.1):

• Treatment and prophylaxis (primary and secondary) of Pneumocytosis jiroveci pneumonitis in adults and children.

• Treatment and prophylaxis of toxoplasmosis

• Treatment of nocardoasis.

The following infections may be treated with co-trimoxazole where there is bacterial evidence of sensitivity to co-trimoxazole and good reason to prefer the combination of antibiotics in co-trimoxazole to a single antibiotic.

• Treatment of urinary tract infections

• Treatment of acute exacerbations of chronic bronchitis

• Treatment of acute otitis media in children

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).